Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VERU-112
- Development stage
- Unknown
- Lead developer
- Veru
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VERU-112 is a small molecule tubulin inhibitor initially developed by Veru for oncology indications. It acts by disrupting microtubule dynamics, inhibiting tubulin polymerization, thereby interfering with mitosis and cell proliferation. VERU-112 belongs to the family of tubulin inhibitors, which target the cytoskeleton within dividing cells. According to available development data, VERU-112's latest global R&D status is discontinued, and it is not approved for any indication[7].
- Brand names
- VERU-112VERU112VERU 112
- Other names
- VERU-112VERU112VERU 112
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on VERU-112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERU-112.